[HT-03-1] Overview of clinical aspects of tauopathies including PSP and CBD

Zbgniew Wszolek (Mayo Clinic Florida)

Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are neuropathologically characterized by accumulation of phosphorylated 4-repeat tau in brain. Clinical diagnosis of PSP and CBD is challenging because correlation between clinical phenotypes and underlying neuropathological findings is often inconsistent. Recently, new criteria for PSP diagnosis have been proposed by the Movement Disorder Society-endorsed Study Group. In addition, genetic analysis and molecular imaging study now provide useful information to make accurate diagnosis of PSP and CBD. With disease-modifying therapies being developed, accurate diagnosis of patients in early-stage disease is becoming more urgent. In this symposium, we will discuss how we can make diagnosis of PSP and CBD efficiently on the basis of recent progress of clinical, genetic, neuropathological and neuroimaging analyses.

[HT-03-2] Early pathological changes of CBD

Helen Ling (Queen Square Brain Bank, Institute of Neurology, University College London)

Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are neuropathologically characterized by accumulation of phosphorylated 4-repeat tau in brain. Clinical diagnosis of PSP and CBD is challenging because correlation between clinical phenotypes and underlying neuropathological findings is often inconsistent. Recently, new criteria for PSP diagnosis have been proposed by the Movement Disorder Society-endorsed Study Group. In addition, genetic analysis and molecular imaging study now provide useful information to make accurate diagnosis of PSP and CBD. With disease-modifying therapies being developed, accurate diagnosis of patients in early-stage disease is becoming more urgent. In this symposium, we will discuss how we can make diagnosis of PSP and CBD efficiently on the basis of recent progress of clinical, genetic, neuropathological and neuroimaging analyses.

[HT-03-3] 進行性核上性麻痺における遺伝子解析研究

矢部一郎 (北海道大学大学院医学研究院神経病態学分野神経内科学教室)

Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are neuropathologically characterized by accumulation of phosphorylated 4-repeat tau in brain. Clinical diagnosis of PSP and CBD is challenging because correlation between clinical phenotypes and underlying neuropathological findings is often inconsistent. Recently, new criteria for PSP diagnosis have been proposed by the Movement Disorder Society-endorsed Study Group. In addition, genetic analysis and molecular imaging study now provide useful information to make accurate diagnosis of PSP and CBD. With disease-modifying therapies being developed, accurate diagnosis of patients in early-stage disease is becoming more urgent. In this symposium, we will discuss how we can make diagnosis of PSP and CBD efficiently on the basis of recent progress of clinical, genetic, neuropathological and neuroimaging analyses.

[HT-03-4] JALPAC: PSP/CBDを対象とした多施設共同コホート研究

池内健¹, JALPAC コンソーシアム² (1.新潟大学脳研究所生命科学リソース研究センター, 2.JALPAC コンソーシアム)

Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are neuropathologically characterized by accumulation of phosphorylated 4-repeat tau in brain. Clinical diagnosis of PSP and CBD is challenging because correlation between clinical phenotypes and underlying neuropathological findings is often inconsistent. Recently, new criteria for PSP diagnosis have been proposed by the Movement Disorder Society-endorsed Study Group. In addition, genetic analysis and molecular imaging study now provide useful information to make accurate diagnosis of PSP and CBD. With disease-modifying therapies being developed, accurate diagnosis of patients in early-stage disease is becoming more urgent. In this symposium, we will discuss how we can make diagnosis of PSP and CBD efficiently on the basis of recent progress of clinical, genetic, neuropathological and neuroimaging analyses.

[HT-03-5] 進行性核上性麻痺と皮質基底核変性症の分子イメージング

石井一成 (近畿大学医学部放射線医学教室放射線診断学部門)

Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are neuropathologically characterized by accumulation of phosphorylated 4-repeat tau in brain. Clinical diagnosis of PSP and CBD is challenging because correlation between clinical phenotypes and underlying neuropathological findings is often inconsistent. Recently, new criteria for PSP diagnosis have been proposed by the Movement Disorder Society-endorsed Study Group. In addition, genetic analysis and molecular imaging study now provide useful information to make accurate diagnosis of PSP and CBD. With disease-modifying therapies being developed, accurate diagnosis of patients in early-stage disease is becoming more urgent. In this symposium, we will discuss how we can make diagnosis of PSP and CBD efficiently on the basis of recent progress of clinical, genetic, neuropathological and neuroimaging analyses.

セッション情報